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Heparan sulfates (HS), a class of glycosaminoglycans, are long
linear complex polysaccharides covalently attached to a protein
core. The HS molecules are made up of repeating disaccharides
onto which modification patterns are superimposed. This re-
sults in a large structural heterogeneity and forms the basis
of specific interactions of HS toward a vast array of proteins,
including growth factors and proteases. To study HS heteroge-
neity in the lung, we used phage display technology to select
seven antibodies against human lung HS. Antibodies reacted
with HS/heparin, but not with other glycosaminoglycans or
polyanions. Sulfate groups were essential for antibody binding.
The amino acid sequence of the antibodies was established,
the complementarity determining region 3 of the heavy chain
containing basic amino acids. The antibodies defined HS epi-
topes with a characteristic tissue distribution. Antibody EV3A1
primarily stained macrophages. Other antibodies primarily
stained basement membranes, but with different preference
toward type of basement membrane. Antibody EV3C3 was the
only antibody which clearly reacted with bronchiolar epithelial
cells. In human lung parenchyma, basic fibroblast growth factor
and vascular endothelial growth factor were largely bound by
HS. Some antibodies blocked a basic fibroblast growth factor–
binding site of HS, and one antibody blocked a vascular endo-
thelial growth factor–binding site of heparin. Taken together,
these data suggest a specific role for HS epitopes in human
lung. The antibodies obtained may be valuable tools to study
HS in pulmonary diseases.
Heparan sulfates (HS) are members of the glycosaminogly-
can (GAG) family, consisting of repeating disaccharide
units onto which modification patterns are superimposed.
HS bind and modulate a myriad of molecules, including
growth factors, cytokines, proteases, antiproteases, matrix
molecules, and viral and bacterial proteins (1, 2). This large
number of interactions suggests an extensive structural vari-
ation within HS. The structural diversity of HS is brought
about by specific chain modifications during the biosynthesis
of HS, including deacetylation, sulfation, and epimerization.
The addition of, e.g., sulfate groups leads to the generation
of specific motifs that make HS highly versatile, protein-
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binding cell regulators (3–5). HS proteoglycans (HSPGs)
are predominantly present on cell surfaces and in the extra-
cellular matrix.
Little is known about the roles proteoglycans and GAGs
play in the lung. However, their distribution over various
lung components (6), their strategic ultrastructural location
(7), and their changes during developmental stages (8) sug-
gest that they are of crucial importance to the architecture
and functioning of the lung. Due to their location in base-
ment membranes and on cell surfaces, HSPGs deserve spe-
cial attention.
The importance of specific HS modifications for lung
functioning has recently been demonstrated in mice lacking
N-deacetylase/N-sulfotransferase-1 (NDST-1), an enzyme
involved in the deacetylation and sulfation of glucosamine
residues in HS. NDST-1/ mice develop respiratory dis-
tress syndrome and die shortly after birth of respiratory
failure (9, 10). This effect has been attributed to immature
type II pneumocytes, resulting in shortage of lung surfac-
tant. Sulfation is a major determinant of the response of
alveolar type II cells to growth factors (11). Growth factors
like fibroblast growth factors are retained by HS. Electron
microscopical studies using cationic probes indicate that HS
in the basement membranes of alveolar type I and type
II cells and of alveolar endothelial cells are differentially
sulfated (12, 13). Sulfated proteoglycans play a central role
in the modulation of the extracellular matrix of pulmonary
fibroblasts, and HSPGs are involved in neutrophil traffick-
ing to the alveolar space (14).
Studies of HSPGs have mainly been focused on the pro-
tein core, whereas research on HS in the lung has been
limited to the estimation of total HS content. Detailed struc-
tural analysis of HS domains have not been performed,
simply because appropriate tools were lacking. Only a few
antibodies that recognize HS epitopes have been generated,
primarily because of the nonimmunogenic nature of HS. To
circumvent this, we adapted the phage display technology to
obtain specific antibodies against HS (15, 16).
In this study, we report on the isolation, characterization,
and application of single chain antibodies selected against
HS isolated from human lung. We provide evidence for the
existence of several, differentially distributed HS epitopes
in human lung, and show that binding of basic fibroblast
growth factor (bFGF) and vascular endothelial growth fac-
tor (VEGF) to the alveolar matrix of human lung is medi-
ated via HS. The antibodies may be very instrumental in
elucidation of the role of HS domains in health and disease.
Materials and Methods
Lung specimens were obtained from patients undergoing lobec-
tomy or pneumonectomy for a localized malignant pulmonary
process, at the University Lung Centre Nijmegen or the Rijnstate
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Hospital Arnhem, the Netherlands. A human semi-synthetic anti-
body phage display library (17) (now officially named synthetic
scFv Library No.1) was generously provided by Dr. G. Winter,
Cambridge University (Cambridge, UK). This library contains 50
different VH genes with a synthetic random complementarity de-
termining region 3 (CDR3) segments, which are 4–12 amino acid
residues in length. The heavy chains are combined with a single
light chain gene (DPL16). The library contains over 108 different
clones and all antibodies contain a c-Myc tag.
All chemicals used were purchased from Merck (Darmstadt,
Germany) unless stated otherwise. Bacterial medium (2xTY) was
from Gibco BRL (Paisley, Scotland); chemically modified heparan
sulfate kit, chemically modified heparin kit, anti-chondroitin sul-
fate (CS)/dermatan sulfate (DS) “stub” antibody (2B6), anti-HS
“stub” antibody (3G10) and chondroitin 4,6-disulfate from squid
cartilage were from Seikagaku Kogyo (Tokyo, Japan). Heparin
from porcine intestinal mucosa, HS from bovine kidney and from
porcine intestinal mucosa, chondroitin 4-sulfate from whale carti-
lage, chondroitin 6-sulfate from shark cartilage, hyaluronate from
human umbilical cord, DNA from calf thymus, dextran sulfate,
sodium azide, bovine serum albumin (fraction V), chondroitinase
ABC (from Flavobacterium heparinum), and rabbit anti-rat bFGF
were from Sigma (St Louis, MO); Microlon 96-well microtiter
plates were from Greiner (Frickenhausen, Germany); polystyrene
Maxisorp Immunotubes were from Nunc (Roskilde, Denmark);
mouse anti–c-Myc monoclonal IgG (clone 9E10) and mouse anti-
VSV monoclonal IgG (clone P5D4) were from Boehringer Mann-
heim (Mannheim, Germany); rabbit anti–c-Myc polyclonal IgG
(A-14) was from Santa Cruz Biotechnology (Santa Cruz, CA);
alkaline phosphatase–conjugated rabbit anti-mouse IgG, mouse
anti-human mast cell tryptase (clone AA1), and mouse anti-human
CD68 (clone KP1), were from Dakopatts (Glostrup, Denmark);
Alexa 488–conjugated goat anti-mouse IgG and Alexa 594–
conjugated goat anti-mouse IgG were from Molecular Probes (Eu-
gene, OR); Mowiol (4–88) was from Calbiochem (La Jolla, CA);
Plasmid DNA isolation kit was from Qiagen (Hilden, Germany);
and ABI Prism Big Dye Terminator Cycle Sequencing Ready
Reaction Kit was from PE Applied Biosystems (Norwalk, CT).
Hematoxylin was from Fluka Biochemika (Buchs, Switzerland).
Mouse anti-human VEGF (ab1316) clone VG1 was from Abcam
(Cambridge, UK). Human recombinant (hr) VEGF-165 and rat
recombinant (rr) bFGF, cloned in prokaryotic vector pQE16, were
a gift from the Department of Pathology, University Hospital
Nijmegen (Nijmegen, The Netherlands). All experiments were
performed at ambient temperature (22C), unless stated otherwise.
Isolation of Heparan Sulfate from Human Lung Tissue
Lung tissue was collected from 8 individuals, 5 were male, and 3
were female. Small lung specimens were taken from resected lung
lobes, not showing any sign of the underlying disease for which
the patient underwent surgery (mostly lung cancer) or obstruction
pneumonia. Subjects (54  7; mean age  SD) had spirometric
values in the normal range. Per gram (wet weight) of human lung
tissue, 4 ml 50 mM sodium phosphate buffer, pH 6.5, containing
2 mM EDTA, 2 mM cysteine, and 10 U papain were added and
digestion was performed for 16 h at 65C. The digest was centri-
fuged (16,000 g for 20 min at 4C) and the supernatant containing
the GAGs was subjected to mild alkaline borohydride digestion
(0.5 M NaOH/0.1 M NaBH4 at 4C) to remove residual peptides
from the GAGs. After overnight digestion, the mixture was neu-
tralized by addition of 6 M HCl. Proteins were precipitated for 30
min at 0C by addition of 100% (wt/vol) trichloroacetic acid to a
final concentration of 15%. Precipitated proteins were removed
by centrifugation (16,000  g for 20 min at 4C), and GAGs were
precipitated by addition of 5 volumes of 100% ethanol to the
supernatant and incubation overnight at 20C. After centrifuga-
tion (16,000  g for 30 min at 4C), the pelleted GAGs were
washed with 70% ethanol, dried, and dissolved in MilliQ. To obtain
GAG preparations which contained only HS, chondroitinase ABC,
which digests chondroitin sulfate and dermatan sulfate, was added
(1 IU/100 mg of GAG in 25 mM Tris-HCl, pH 8.0) and incubation
was performed for 16 h at 37C. The efficacy of chondroitinase
ABC treatment was evaluated by agarose gel electrophoresis (18).
HS were further purified using DEAE Sepharose column chroma-
tography (18), using 0.2 M, 0.5 M, 1.0 M and 2.0 M NaCl in 10
mM Tris-HCl elution steps, pH 6.8. The 0.5 and 1.0 HS fractions
were pooled, ethanol-precipitated, and residual salt removed by
a 70% (vol/vol) ethanol wash. HS preparations were dissolved in
MilliQ, checked for purity (Figure 1) and stored at 4C.
Selection of Anti-GAG Antibodies
Phage display-derived antibodies were obtained as described (15)
using four rounds of panning against HS (0.5 M and 1.0 M fraction).
Briefly, antibody-expressing phages were added to HS-coated
tubes, and bound phages were eluted at high pH to allow for the
infection of Escherichia coli TG1 cells. After overnight amplifica-
tion, phages were rescued by the addition of helper phage and
used for further rounds of selections.
Screening for Bacteria Expressing Antibodies
against Glycosaminoglycans
Screening for bacteria expressing anti-HS antibodies was as de-
scribed (15). Briefly, single colonies picked from the last two rounds
of selection were grown in 96-well polystyrene plates until bacterial
growth was visible. Antibody production was induced by the addition
of isopropyl--D-thiogalactopyranoside (IPTG; final concentration
1 mM). Plates were centrifuged, and the supernatant containing
soluble antibodies was applied to wells of polystyrene microtiter
plates previously coated with HS. Bound antibodies were detected
using mouse anti–c-Myc, followed by incubation with alkaline phos-
phatase–conjugated rabbit anti-mouse IgG. Alkaline phosphatase
activity was measured using p-nitrophenyl phosphate as a substrate.
Absorbance was measured at 405 nm. To establish the CDR3 and
VH gene DNA segments, antibody expressing clones were sequenced
using PelB-seq (5-CCGCTGGATTGTTATTACTC-3) (located
within the PelB leader sequence), and For Link-seq (5-GCCACCT-
CCGCCTGAACC-3) (located in the linker region between the VH
and the VL genes). For this purpose, double-stranded DNA was
isolated using standard procedures.
Large Scale Preparation of Antibodies
To obtain large amounts of soluble antibodies, periplasmic frac-
tions from infected bacteria were isolated (15). Briefly, bacteria
were grown at 37C until an optical density (OD600) of 0.5 was
reached. Induction was effectuated by the addition of IPTG. After
Figure 1. Agarose gel electro-
phoresis of human lung HS
used for biopanning. The gel
was run in 50 mM Ba(Ac)2 pH
5.0 and stained by a combined
azure A-silver procedure. M,
marker; lane 1: total lung
GAG; lanes 2 and 3: human
lung HS after DEAE sepha-
rose column chromatography
(eluting at 0.5 M NaCl [2], and 1.0 M NaCl [3] followed by chondroi-
tinase ABC digestion). HS, heparan sulfate; DS, dermatan sulfate;
CS, chondroitin sulfate.
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incubation at 30C for 3 h, the culture was centrifuged, and the
pellet was resuspended in 200 mM sodium borate buffer (pH 8.0)
containing 160 mM NaCl, and an ethylenediaminetetraacetic acid
(EDTA)-free protease inhibitor cocktail (1 mM). After centrifuga-
tion at 5,000  g for 30 min at 4C, the supernatant (representing
the periplasmic fraction containing the antibodies) was filtered
through a 0.45 m filter, dialyzed overnight at 4C versus phosphate-
buffered saline (PBS), and stored at 20C.
Characterization of Antibodies by Enzyme-Linked
Immunosorbent Assay
Affinity of the antibodies to various molecules was evaluated by
enzyme-linked immunosorbent assay (ELISA) as described (15).
Briefly, wells were coated with the molecules concerned by incuba-
tion with 100 l of a 10 g/ml solution in wells of a 96-well microti-
ter plate for 16 h at 4C. The wells were rinsed with PBS containing
0.1% (vol/vol)Tween-20 (PBST) and blocked with 2% bovine se-
rum albumin (BSA) in PBS containing 0.05% (vol/vol) Tween-20.
Antibodies were added and allowed to bind for 90 min. Bound
antibodies were detected by incubation with 10-fold diluted mouse
anti–c-Myc monoclonal antibody 9E10, followed by incubation
with 1:1,000 diluted alkaline phosphatase–conjugated rabbit anti-
mouse IgG. The plates were rinsed six times with PBST following
each incubation. Enzyme activity was detected using 100 l 1 mg
p-nitrophenyl phosphate/ml 1 M diethanolamine/0.5 mM MgCl2,
pH 9.8, as a substrate. Absorbance was read at 405 nm. All assays
were performed at least three times and representative results
are shown. As a control, wells were incubated with an irrelevant
antibody TSC01 (CDR3 sequence LGFHS, VH3 family, germline
segment DP40).
To evaluate which chemical groups are important for recogni-
tion of the antibodies, an ELISA with modified HS/heparin prepa-
rations (from porcine intestine) was performed, including heparins
that were desulfated and N-sulfated, desulfated and N-acetylated,
N-desulfated and N-acetylated, and various HS preparations. Per-
iplasmic fractions containing antibodies were incubated for 90 min
in 96-well microtiter plates previously coated with modified hepa-
rin/HS preparations. The plates were rinsed with PBST and ELISA
was performed as described above.
Characterization of Antibodies and Localization of HS
Epitopes by Immunohistochemistry
Human lung cryosections (5 m) were fixed in 4% paraformalde-
hyde. After rinsing in PBS for 10 min, cryosections were incubated
in hydrogen peroxide solution (0.3% in PBS, pH 7.3) to quench
endogenous peroxidase activity. Subsequently, cryosections were
washed for 10 min in PBS, blocked with PBS containing 0.05%
(vol/vol) Tween-20 and 2% (wt/vol) BSA for 10 min, and incubated
with 2-fold diluted antibodies containing 3% normal horse serum
for 45 min. Bound antibodies were detected by incubation with
1:10 diluted mouse anti–c-Myc monoclonal antibody 9E10 con-
taining 3% normal horse serum for 45 min. After washing with
PBST (2  10 min), cryosections were incubated with biotinylated
anti-mouse IgG containing 3% normal horse serum, for 45 min,
washed with PBST (2  10 min), and incubated with Vectastain
Elite ABC-kit (Vector, Burlingame, CA) for 45 min. Sections were
rinsed in PBST and incubated with 3,3-diaminobenzidine (DAB)
solution to identify bound antibody. After a final wash in PBS,
sections were counterstained with Mayers’ hematoxylin and
mounted with Entellan (Merck, Darmstadt, Germany). As a con-
trol, cryosections were incubated with an irrelevant antibody
TSC01.
To evaluate the specificity of the antibodies, cryosections were
digested with the glycosidases heparinase III, heparinase I (both
digest HS) 0.04 IU/ml in 50 mM NaAc/50 mM Ca(Ac)2, pH 7.0
or chondroitinase ABC (digests chondroitin sulfate and dermatan
sulfate) 0.02 U/ml in 25 mM Tris-HCl, pH 8.0, (2 h at 37C, refreshing
the enzyme after 1 h). As a control, cryosections were incubated in
reaction buffer without enzyme. After washing three times with
PBS and blocking for 30 min with PBS containing 0.05% (vol/vol)
Tween-20 and 2% (wt/vol) BSA, cryosections were incubated with
antibodies and processed for immunohistochemistry as described
above. The efficiency of heparinase III and chondroitinase ABC
treatment was evaluated by incubation of cryosections with antibod-
ies against GAG-“stubs,” generated by the glycosidases. For HS
stubs the antibody 3G10 was used. For chondroitin sulfate stubs the
antibody 2B6 was used. All tests were performed at least three
times.
To evaluate whether the antibodies react with heparin or mast
cells in situ, human lung cryosections were rehydrated, blocked
with PBS containing 0.05% (vol/vol) Tween-20 and 2% (wt/vol)
BSA for 30 min, and incubated with 2-fold diluted antibodies for
90 min. Bound antibodies were detected using 1:100 diluted anti–
c-Myc rabbit polyclonal antibody A-14 and goat anti-rabbit IgG
Alexa 488, each for 60 min. For detection of mast cell tryptase,
1:500 diluted mouse anti-human mast cell tryptase and goat anti-
mouse IgG Alexa 594 were included in the incubations. Macro-
phages were detected by 1:500 diluted CD68, and goat anti-mouse
IgG Alexa 594. After each incubation, cryosections were washed,
fixed in 100% methanol, air-dried, and embedded in Mowiol (10%
[wt/vol] in 0.1 M Tris-HCl, pH 8.5/25% [vol/vol] glycerol/2.5%
[wt/vol] NaN3). As a control, cryosections were incubated with an
irrelevant antibody TSC01.
Inhibition of Antibody Binding to Heparin and HS by
bFGF and VEGF
To study whether the HS epitope defined by the antibodies is
involved in the binding of bFGF and/or VEGF, polystyrene micro-
titer plates were coated with HS from bovine kidney or heparin
from porcine intestinal mucosa. Subsequently, 100 l of a solution
containing bFGF- (19) or VEGF-165 (0.3 g/ml PBS, containing
0.05% [vol/vol] Tween-20 and 2% [wt/vol] BSA) was applied for 60
min to wells of the polystyrene microtiter plate. At these amounts, a
maximum number of bFGF- or VEGF-165–binding sites on HS
and heparin are occupied, as determined using anti–growth factor
antibodies. After washing, antibodies were applied. The amount
of antibodies was chosen such that, in an ELISA without growth
factors, 50% staining was obtained, 100% being the value obtained
using saturating amounts of antibody. This set-up was chosen to
sensitively detect a reduction of HS-bound antibodies by growth
factors. Bound antibodies were detected as described.
Results
Selection of Anti-HS Antibodies
A human synthetic phage library containing phages express-
ing antibodies was biopanned against HS isolated from hu-
man lung. After four rounds of panning, seven antibodies
were selected (Table 1). The antibodies were different with
respect to their amino acid sequence of the complementarity-
determining region 3 and/or VH gene.
Characterization of Anti-HS Antibodies
Using ELISA, antibodies were shown to be reactive for the
lung HS preparation as well as for heparin, a highly sulfated
form of HS. HS from other sources was also recognized,
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except for EV3A1, which only reacted with heparin (Table
2). None of the antibodies was reactive with other glycosami-
noglycans such as dermatan sulfate and chondroitin 4-sulfate,
chondroitin 6-sulfate, hyaluronic acid, keratan sulfate and K5
(similar to the HS precursor polysaccharide), nor with other
polyanionic molecules such as dextran sulfate and DNA.
Analysis of HS Epitopes Recognized by the Antibodies
To determine which chemical groups are important for recog-
nition, we tested all seven antibodies for reactivity with chem-
ically modified heparin and HS preparations (Table 2).
None of the antibodies reacted with K5 capsular polysac-
charide from E. coli (which is similar to the HS precursor
polysaccharide), indicating that additional modifications are
essential for binding. Except for antibodies EV4D12 and
EV4D4, none of the antibodies reacted with heparin that
was completely desulfated/N-acetylated, desulfated but N-
sulfated heparin, or N-desulfated/N-acetylated, indicating
that N- and O-sulfate groups are essential. Only antibody
EV4D12 reacted, although weakly, with heparin that was
completely desulfated and N-sulfated, suggesting that N-
sulfation is of major importance for the binding of this
antibody. Antibody EV4D6 was the only antibody which
partially recognized N-desulfated and N-acetylated heparin
(but not HS), indicating that the presence of N-sulfate
groups is not absolutely essential for binding.
Localization of HS Epitopes in Human Lung
To study the location of the HS saccharides defined by
the antibodies, we performed immunohistochemistry using
cryosections of human lung. Each antibody showed a de-
fined pattern of reactivity (Table 3, Figure 2: shown are the
antibodies EV3C3 [a], EV4D12 [b], EV3D6 [c], EV3A1
[d], and anti-stub antibody 3G10 [e]). All antibodies, except
for EV3A1 and EV3D6, primarily stained basement mem-
branes of alveoli, bronchioli, and blood vessels. The antibod-
ies differed in preference toward different types of basement
membranes. EV3D6 was the only antibody which was only
reactive with basement membranes of bronchioli and blood
vessels (Figure 2, c1–c2). Basement membranes of alveoli
were not recognized by EV3D6. For the other antibodies,
TABLE 1
Characteristics of anti-HS antibodies
Antibody CDR3 sequence VH family Germline segment
EV3A1 GKRRRQ VH-3 DP-42
EV3B2* GKMKLNR VH-3 DP-38
EV3C3* GYRPRF VH-3 DP-42
EV3D6 WMHLRVRH VH-1 DP-5
EV4D6 GARPRAN VH-3 DP-38
EV4D12 HAPLRNTRTNT VH-3 DP-38
EV4F8 GMRPRL VH-3 DP-38
Given are the antibody code, amino acid sequence of the VH complementarity-
determining region 3 (CDR3), VH family and the germline segment (DP number-
ing). CDR3 sequences are shown in single-letter amino acid code. VH families and
DP segments were deduced from the V BASE using DNAPLOT alignment (http://
www.mrc-cpe.cam.ac.uk/imt-doc/restricted/DNAPLOT.html) by applying the full-
length VH sequences of the anti-HS antibody clones (nomenclature according to
Tomlinson and coworkers [40]).
* Antibodies EV3B2 and EV3C3 have been partially described (15).
staining intensity of basement membranes of blood vessel
endothelium, bronchioles, and capillaries was identical, or
stronger compared with alveolar basement membranes.
Basement membranes of smooth muscle cells of blood vessels
and bronchioli were recognized by the antibodies EV3C3,
EV4D12 (Figure 2, a1–a2, b1–b2), and antibody EV3B2 (not
shown), whereas the other antibodies were completely nega-
tive. Antibody EV3A1 was primarily reactive with macro-
phages (Figures 3c and 3d). It stained granules of uneven
size, likely lysosomes. It was not reactive with mast cells
(Figures 3a and 3b). EV3C3 was the only antibody which
clearly stained the epithelial cells of bronchioli (Figure 4a);
other antibodies (e.g., EV4D12, Figure 4b) were negative in
this respect. Note that EV3C3, but not EV4D12, shows a
distinct intracellular staining in bronchiolar epithelium. Nu-
clei of bronchiolar cells appeared to be reactive with EV3C3
(Figure 4a, insert). Macrophages were recognized by all anti-
bodies, except for EV3D6 and EV4D6 (data not shown).
Mast cells were recognized by the antibodies EV3B2, EV3C3,
and EV3F8 (data not shown). Thus, the staining patterns of
anti-HS antibodies show a unique distribution of HS epitopes
in human lung.
To ascertain HS specificity of the antibodies, cryosec-
tions of human lung tissue were treated with heparinase
III, heparinase I, or chondroitinase ABC, before incubation
with the antibody. Staining was absent or strongly decreased
after treatment with heparinase III (Figure 2, a3–d3),
whereas treatment with chondroitinase ABC had no effect
(data not shown). For antibody EV3A1 staining of macro-
phages was not abolished by treatment with heparinase III,
nor with heparinase I. For antibody EV3C3 some staining
at discrete, but unidentified, places in the alveolar wall still
remained after treatment with heparinase III (Figure 2, a3).
After treatment with heparinase I, however, staining was
completely lost.
Inhibition of Antibody Binding by bFGF and VEGF
To study if antibody-defined HS saccharides were involved
in growth factor binding, the inhibition of antibody binding
to HS/heparin by bFGF and VEGF was studied. Using
bFGF, binding of antibody EV3C3 to HS was blocked by
22  2%, EV3B2 by 14  4%, and EV4F8 by 19  2%
(values are mean  SD, n  4). In case of heparin, only
antibody EV3A1 was blocked by 39  3%. For VEGF,
only binding of antibody EV3A1 to heparin could be slightly
inhibited (11  1%). No effect of VEGF was observed for
the other antibodies. In tissue, endogenous bFGF could be
detected at sites of basement membranes (Figure 5, a1),
and staining was removed after heparinase III treatment
(Figure 5, a2). After applying recombinant bFGF, most
basement membranes were stained (Figure 5, b1), and stain-
ing was decreased after heparinase III treatment (Figure 5,
b2). No endogenous VEGF could be detected. Recombi-
nant VEGF-165 added to the sections was located in base-
ment membranes of alveoli, blood vessels, bronchioli, and
macrophages (Figure 5, c1). Heparinase III digestion greatly
abolished VEGF binding to sections (Figure 5, c2).
Discussion
In this study we describe the selection of seven antibodies
against human lung HS from a semi-synthetic phage display
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TABLE 2
Reactivity of anti-HS antibodies with modified HS and heparin molecules
Antibody Code
Test Substance EV3A1 EV3B2 EV3C3 EV3D6 EV4D6 EV4D12 EV4F8
Heparin, porcine intestinal mucosa 	 		 	 		 		 	 		
Heparin, N-desulfated and N-acetylated     	/  
Heparin, completely desulfated and N-sulfated      	/ 
Heparin, completely desulfated and N-acetylated       
HS, bovine kidney  	 	 	 	 	 	
HS, intestinal mucosa  	 	/ 	/ 	 	 	
HS, N-desulfated and N-acetylated       
K5, capsular polysaccharide from E. coli*       
Periplasmic fractions of the antibodies were applied to various GAG preparations immobilized on microtiter plates. Bound antibodies were detected using anti-
c-Myc mouse monoclonal antibody 9E10, followed by alkaline phosphatase–conjugated rabbit anti-mouse IgG, after which enzymatic activity was measured using
p-nitrophenyl phosphate as a substrate. Substrate affinity: 		, very strong; 	, strong; 	/, moderate; , absent (n  3).
* Similar to the HS precursor polysaccharide.
library. Phage display has proven to be a very useful tech-
nique to select antibodies against poorly immunogenic mol-
ecules, such as HS. All antibodies selected in this study
recognize different HS epitopes, as indicated by their stain-
ing patterns and reactivity toward various HS preparations.
For all antibodies, the CDR3 region of the heavy chain,
which is of prime importance for the specificity and affinity
of the antibodies, contained two or more basic amino acid
residues likely involved in binding to negatively charged
HS. HS-binding consensus sites contain basic amino acids,
e.g., XBBXBX (B, basic amino acid residue; X, any amino
acid residue [20]). Three out of seven antibodies bear the
sequence GX1RPRX2 (X1: any amino acid; X2: hydrophobic
amino acid). We suggest that this sequence forms a potential
GAG-binding site.
Of the seven antibodies selected against lung HS, two
(EV4D12 and EV4F8) are identical to antibodies selected
against HS from bovine kidney and human skeletal muscle
(15, 16). Their CDR3 sequences are HAPLRNTRTNT and
GMRPRL, and it indicates that common HS saccharides are
present in these organs. The position of sulfate groups is of
TABLE 3
Immunostaining for HS epitopes defined by anti-HS antibodies
Antibody Code
Structure EV3A1 EV3B2 EV3C3 EV3D6 EV4D6 EV4D12 EV4F8
Alveoli
Basement membrane epithelium  	/ 	  	/ 	/ 	/
Basement membrane capillaries  	 		  	 		 	
Bronchioli
Epithelial cells   	    
Basement membrane epithelial cells 	 	 		 	 	 		 	
Basement membrane smooth muscle cells  	 	   	/ 
Blood vessels
Basement membrane endothelium 	 	 		 	 	 		 		
Basement membrane smooth muscle cells  	/ 	   	/ 
Mast cells  	 	    	
Macrophages 		 	 	   	 	/
Periplasmic fractions of bacteria expressing anti-HS antibodies were applied to cryosections of human lung. Bound antibodies were visualized by incubation with
anti-c-Myc mouse monoclonal antibody 9E10, followed by biotinylated anti-mouse IgG. Sections were counterstained with Mayers’ hematoxylin. Staining: 		, strong;
	, moderate; 	/, weak; , absent (n  3).
major importance for the binding of the antibodies. The
requirement of both N- and O-sulfate groups for epitope
recognition was indicated by chemically modified heparins.
Overall desulfation completely abolished recognition by all
antibodies. N-resulfation could not restore the heparin–
antibody interaction, except (partly) for EV4D12. N-desulfa-
tion abolished reactivity with all antibodies, except EV4D6.
Because CS as well as DS were not bound by any of the
antibodies, sulfation patterns specific for HS are likely to be
important in the structure of the epitopes involved in binding.
For two antibodies (EV3A1 and EV3C3), staining could
not be completely abolished using heparinase III treatment.
For EV3A1, treatment with heparinase III abolished
staining of basement membranes, but not of macrophages
(Figure 2, d3). Treatment with heparinase I also did not
remove staining. Staining for HS/heparin stubs, generated
by heparinases, was positive after treatment with heparinase
I, but not III, indicating that the HS/heparin in macrophages
is not a substrate for heparinase III and therefore probably
not bound to a core protein (heparinase III cleaves HS in
a region near the core protein, and HS is then washed away
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Figure 2. Immunostaining for HS epitopes defined by anti-HS anti-
bodies. Nontreated and heparinase III–treated cryosections of hu-
man lung were incubated with periplasmic fractions containing
antibody EV3C3 (a ), EV4D12 (b), EV3D6 (c), EV3A1 (d ), or
anti-heparan sulfate stub antibody (3G10) (e). Bound antibodies
were visualized by incubation with anti–c-Myc mouse monoclonal
antibody 9E10, followed by biotinylated anti-mouse IgG. Sections
were counterstained with Mayers’ hematoxylin. Untreated tissue
(a1–d1, a2–d2) showed HS epitopes differentially distributed through-
out parenchymal tissue (for details see text). Staining was lost or
strongly decreased after heparinase III treatment (a3–d3), indicat-
ing the HS-nature of the epitopes. Staining of heparan sulfate stubs
in heparinase III–treated tissue showed alveolar HS to be present
in alveolar and capillary basement membranes (e2–e3). Alveolar
macrophages are negative (arrow in e2). Scale bars: 20 m.
from the tissue section). This situation may be analogous
to that of heparin in mast cells. In mast cells heparin is not
bound to a core protein (it is cleaved off by an endogenous
endoglucuronidase) and also cannot be washed out after
treatment with heparinase I, probably because of a tight
binding of heparin (fragments) to positively charged mole-
cules (histamine, proteases). Also, 3-O sulfation of glucos-
amine residues inhibits cleavage of heparin at that site (21),
and heparin with a high degree of 3-O sulfation may be
more resistant to heparinase I digestion compared with
heparin, which is less 3-O sulfated.
Figure 3. Staining of macrophages by antibody EV3A1. Cryosec-
tions of human lung were incubated with periplasmic fractions
of antibody EV3A1 (a, c). Bound antibodies were visualized by
incubation with rabbit polyclonal anti–c-Myc IgG, followed by
Alexa 488–conjugated goat anti-rabbit IgG. Tryptase, identifying
in mast cells, was visualized using mouse anti-human mast cell
tryptase, followed by Alexa 594–conjugated goat anti-mouse IgG
(b). Macrophages were visualized using mouse anti-human CD68,
followed by Alexa 594–conjugated goat anti-mouse IgG (d ). Note
that EV3A1 reacted strongly with macrophages, but not mast cells.
Scale bar: 50 m.
For antibody EV3C3, heparinase III abolished basement
membrane staining but not staining at some regions in the
alveolar wall. Heparinase I, however, abolished all staining.
Heparinase III cleaves primarily at unsulfated hexuronic
acid residues, especially if there are relatively few sulfate
groups on the adjacent residues. In contrast, heparinase I
prefers highly sulfated regions including sulfated iduronic
acid residues. Therefore, we suggest that EV3C3 recognizes
highly sulfated regions in HS. Possibly, although speculative,
free EV3C3-positive HS, not bound to a core protein, stick
to positively charged areas in the alveolar wall and can only
be removed by more extensive digestion by heparinase I.
Our results implicate that in human lung at least seven
different HS epitopes are present. Already in the early sevent-
ies it was recognized that pulmonary HS are exceptionally
Figure 4. Staining of bronchiolar epithelium by antibody EV3C3.
Cryosections were incubated with antibody EV3C3 (a) and
EV4D12 (b). Bound antibodies were visualized by incubation with
anti–c-Myc mouse monoclonal antibody 9E10, followed by biotin-
ylated anti-mouse IgG. Sections were counterstained with Mayers’
hematoxylin. Note that EV3C3, but not EV4D12, shows a distinct
intracellular staining in the bronchiolar epithelium, nuclei ap-
pearing to be positive (insert). Single arrows, epithelial cells of
bronchioli; double arrows in a, detached epithelial cells. Scale bars:
10 m.
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Figure 5. Localization of bFGF and VEGF in human lung. Non-
treated (a1–c1) and heparinase III–treated (a2–c2) cryosections of
human lung were incubated with an antibody to bFGF (a, b) or
VEGF (c). Sections b and c were pretreated with 20 g/ml bFGF
or VEGF before incubation with the antibody to bFGF or VEGF.
Heparinase III treatment removed endogenous bFGF (a2), and
reduced binding of recombinant bFGF and recombinant VEGF to
sections (b2, c2). After digestion with heparinase III, endogenous
bFGF could not be detected (a2). Staining of sections treated
with heparinase III before incubation with bFGF or VEGF was
markedly decreased (b2 and c2). Scale bar: 50 m.
diverse with respect to sulfation (22–24). The biosynthesis of
HS allows for a large number of different epitopes. First a
precursor polysaccharide is formed, which is subsequently
subjected to a number of modifications (25). Regions where
the precursor molecule is not modified consist of D-glucuronic
acid-N-acetyl-glucosamine (GlcA-GlcNAc) repeats and are
known as N-acetylated (NA) domains. These act as spacers
between the highly modified and sulfated domains (S-
domains). In these S-domains, extensive modifications oc-
cur, especially additions of sulfate groups and epimerisation
of GlcA to IdoA. The bifunctional enzyme NDST catalyzes
the first modification. Mice deficient in NDST isoform 1,
but not 2, die shortly after birth due to respiratory failure
caused by immaturity of type II pneumocytes, which results
in insufficient production of surfactant (9, 10). This indicates
that NDST-1, but not -2, is essential for the maturation of
type II pneumocytes, and implies the importance of specific
sulfate patterns in HS. NDST-1–deficient mice have under-
sulfated HS in which N-sulfation and 2-O sulfation are
reduced, but in which 6-O sulfation is normal (9, 26). The
antibodies identified in this study recognize specific sul-
fation patterns and may be valuable tools to study HS sac-
charides in health and disease.
A well recognized feature of HS/heparin is the binding
of growth factors. bFGF could (partially) prevent three (out
of seven) antibodies to bind to HS. This suggests that a
number of antibodies are not recognizing domains in HS/
heparin involved in binding bFGF/VEGF. The three anti-
bodies that were blocked cover the sites to which bFGF
binds in sections. Interestingly, these three antibodies are
the only ones reactive with mast cells (see Table 3). In the
case of VEGF, only antibody EV3A1 could be partially
inhibited by VEGF from binding to heparin, and this anti-
body did not completely cover the structures reactive with
exogenously applied VEGF. The binding of growth factors
to immobilized HS in ELISA may be quite weak. It should
be noticed that in tissue, HS chains are clustered on a core
protein in a way that is probably not possible in microtiter
plates. In tissue, therefore, a multivalency effect may be
expected which results is a stronger binding of growth factors
compared with that seen in ELISA. In this respect it is notable
that for example for glypican-1 (a HS-proteoglycan) a Kd of
0.12 nM has been found for VEGF-165, which is considerably
lower than what is generally found for HS (27).
The staining patterns of the antibodies raise curiosity
about the function of the distinct HS epitopes involved in
human lung. Antibody EV3A1 showed a quite different
staining pattern compared with the other antibodies, as it
reacted strongly with macrophages. Frevert and coworkers
(28) showed positive staining for HS on the cell surface of
alveolar macrophages. Macrophages are distributed through-
out connective tissues and participate in both defense- and
injury-related processes (29). They are thought to play a
central role in the fibroproliferative response, and studies
indicate that they produce bFGF (30) and generate an abun-
dant amount of VEGF (31). Interestingly, EV3A1 was the
only antibody that could compete with VEGF for HS. In
lung the role of VEGF, which is bound by HS, has recently
attracted much attention. In rats, a blockade of the VEGF
receptor results in lung alveolar cell apoptosis and emphy-
sema (32, 33). In humans, lung tissue from patients with
emphysema contains less VEGF compared with controls.
Also, lower levels of VEGF in sputum correlate well with
lower FEV1 and DlCO levels (34).
Proteoglycans and GAGs may have a specific role in the
pathogenesis of pulmonary diseases. Next to binding and
modulation of growth factors/cytokines, GAGs (especially
HS) can function as strong inhibitors of neutrophil elastase
(35–37), and may thus influence the protease/antiprotease
balance. Alterations in HS would have consequences for the
protective HSPG barrier of the alveolus (7). In the urine of
patients with emphysema, a decreased content of the HS
epitope JM403 was found together with a normal content of
HS (38), suggesting a structural alteration in or an altered
processing of HS molecules in the lungs of emphysematous
patients. Studies on chemically and enzymatically modified
HS indicate that the JM403 epitope contains one or more
N-unsubstituted glucosamine and D-glucuronic acid units,
and is located in a region of the HS chain composed of mixed
N-sulfated and N-acetylated disaccharide units (39). This is
an example of a structural alteration in HS associated with
a pulmonary disease. The availability of seven HS epitope-
specific antibodies further allows to identify changes in the
fine structure of HS associated with pulmonary conditions.
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In conclusion, using phage display technology seven anti-
bodies were selected against HS from human lung. Antibod-
ies recognize different epitopes and some of them compete
with growth factor for binding to HS. The binding of bFGF
and VEGF to the alveolar matrix of human lung is likely
to be mediated via HS. The availability of anti-lung HS
antibodies and their encoding DNAs may provide valuable
tools to study more accurately alterations in HS in health
and disease.
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